TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31710011

Group type: EXPERIMENTAL
Intervention: Sesame oil (SO)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ozonated sesame oil (OSO)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (CHX)
Number of subjects: 75
Study: 28286189

Group type: EXPERIMENTAL
Intervention: Dried aqueous spearmint extract (600 mg/day) for 90 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dried aqueous spearmint extract (900 mg/day) for 90 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26420770

Group type: EXPERIMENTAL
Intervention: Individualised intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no extra care)
Number of subjects: 43
Study: 23713310

Group type: EXPERIMENTAL
Intervention: Auricular point group A (magnetic beads on specific auricular points)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Auricular point group B (magnetic beads on preauricular and retroauricular points)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group (plasters on corresponding auricular points)
Number of subjects: 120
Study: 21899741

Group type: EXPERIMENTAL
Intervention: 3 g cinnamon
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17538539

Group type: EXPERIMENTAL
Intervention: 1.6 g/day of plant sterols (PS) for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3.0 g/day of plant sterols (PS) for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tall oil (TO) containing 78% sitosterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean oil (BO) containing 27% campesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) withdrawal
Number of subjects: 0
Study: 17511685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Steroid (methylprednisolon)
Number of subjects: 110
Study: 15076013

Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 11688766

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (NI) 30-60 mg once a day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Amlodipine (AM) 5-10 mg once a day
Number of subjects: 54
Study: 9507416

Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation of the posteroventral internal pallidum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulation turned off
Number of subjects: 0
Study: 7837683

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (omeprazole 20mg once daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: H2-blocker (famotidine 20mg twice daily)
Number of subjects: 11
Study: 3045781

Group type: EXPERIMENTAL
Intervention: Erythromycin (40 mg/kg/day for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dicloxacillin (25 mg/kg/day for 10 days)
Number of subjects: 100
Study: 29131285

Group type: EXPERIMENTAL
Intervention: Standardised tomato extract (STE)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 82
Study: 27650864

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study: 24912561

Group type: EXPERIMENTAL
Intervention: Balance rehabilitation aimed at improving motor and sensory strategies
Number of subjects: 53

Group type: COMPARATOR
Intervention: Rehabilitation treatment which did not include training of sensory strategies
Number of subjects: 53
Study: 22809962

Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20509752

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d. + Amoxicillin 1000 mg + Clarithromycin 500 mg for 1 week followed by placebo for 3 weeks
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d. + Placebo antibiotics for 1 week followed by Esomeprazole 20 mg o.d. for 3 weeks
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg o.d. after initial treatment
Number of subjects: 401

Group type: COMPARATOR
Intervention: Esomeprazole alone
Number of subjects: 401
Study: 18793576

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 24
Study: 16035144

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 15 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 45 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12236071

Group type: EXPERIMENTAL
Intervention: Sustained-release sparfloxacin chip (SRS chip)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10037246

Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg/h)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TRH + GHRH + GHRP-2
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg/h)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TRH (1 microg/kg/h)
Number of subjects: 86
Study: 7669991

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine 75 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Baseline examination (responders vs non-responders)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hippocampal volume
Number of subjects: 8
Study: 1823750

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7193918

Group type: COMPARATOR
Intervention: i.v. DDAVP (0.1‐0.4 μg/Kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: i.n. DDAVP (1‐4 μg/Kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: i.v. DDAVP (0.4 μg/Kg) single dose
Number of subjects: 17

Group type: COMPARATOR
Intervention: i.v. DDAVP (0.4 μg/Kg) repeated doses
Number of subjects: 17
Study: 31688513

Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training at 30% maximal voluntary contraction, 3 days/week for 6 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 11
Study: 28684276

Group type: EXPERIMENTAL
Intervention: Capsaicin (100µg/50µl) administered into ST36 or ST37 acupoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin administered into ST36 acupoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 43°C heating-needle stimulation applied to ST36 acupoint for 30-45 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-emptive treatment of contralateral ST36 acupoint with 43°C heating-needle stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-acupoint area treatment
Number of subjects: 0
Study: 25976567

Group type: EXPERIMENTAL
Intervention: S-line blood-liquid warmer with Mediset infusion set
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrafix Primeline Confortset (IPC)
Number of subjects: 20
Study: 23372363

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Three-port laparoscopic cholecystectomy (TPLC)
Number of subjects: 102
Study: 21330044

Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mouth-to-pocket mask ventilation (MPV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bag-valve-mask ventilation (BMV)
Number of subjects: 60
Study: 18931095

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg/day
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg/day
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Liraglutide (all doses)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1091
Study: 17450978

Group type: EXPERIMENTAL
Intervention: individual‐group‐individual technique
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: nominal group technique
Number of subjects: 149

Group type: COMPARATOR
Intervention: nonstructured interactive groups (Control)
Number of subjects: 149
Study: 15059710

Group type: EXPERIMENTAL
Intervention: DHA (400 mg/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12008788

Group type: EXPERIMENTAL
Intervention: Pleconaril 400 mg three-times daily for 7 days
Number of subjects: 587

Group type: COMPARATOR
Intervention: Pleconaril 400 mg three-times daily
Number of subjects: 587
Study: 9513910

Group type: EXPERIMENTAL
Intervention: F80B dialyzer (high-flux polysulfone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: T220L dialyzer (high-efficiency cellulose)
Number of subjects: 6
Study: 7652038

Group type: EXPERIMENTAL
Intervention: Experimental (stress) condition
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 33
Study: 2569485

Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen plus 60 mg phenyltoloxamine citrate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen alone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 356078

Group type: EXPERIMENTAL
Intervention: diastolic blood pressure feedback, electromyographic feedback, and verbal relaxation
Number of subjects: 22

Group type: COMPARATOR
Intervention: sham blood pressure feedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 22
Study: 31340845

Group type: EXPERIMENTAL
Intervention: Flat marginal endocrown
Number of subjects: 200

Group type: COMPARATOR
Intervention: 90-degree shoulder marginal endocrown
Number of subjects: 200
Study: 28644243

Group type: EXPERIMENTAL
Intervention: MASK (room air through a tightly fitting face mask)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No‐MASK (room air without mask)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No‐MASK + O2 (10 l/min of oxygen via nasal cannula)
Number of subjects: 27
Study: 27039086

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions of real acupuncture)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham group (10 sessions using a Streitberger needle)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 70
Study: 24814691

Group type: COMPARATOR
Intervention: Primary surgery alone (34 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Primary surgery combined with postoperative radiotherapy (26 patients)
Number of subjects: 60
Study: 23106752

Group type: EXPERIMENTAL
Intervention: Advocacy efforts by parents and support workers
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Parental advocacy
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Support worker advocacy
Number of subjects: 197
Study: 19411106

Group type: EXPERIMENTAL
Intervention: MDS-RA patients with abnormal karyotype
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control groups (46 MDS-RA patients with normal karyotype and 207 patients with non-MDS anemia)
Number of subjects: 301
Study: 17323786

Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol PO (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: metoprolol tartrate 50 mg PO (n = 10)
Number of subjects: 20
Study: 15481851

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 1,350 mg/day
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 2,250 mg/day
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (all doses)
Number of subjects: 196
Study: 11479411

Group type: EXPERIMENTAL
Intervention: Oral inoculation with 106 viable cells of plasmid-free human E. coli within 2 hours after birth
Number of subjects: 102

Group type: COMPARATOR
Intervention: Heat-killed bacteria
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral inoculation with 106 viable cells of plasmid-free human E. coli
Number of subjects: 102
Study: 10743849

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7826567

Group type: EXPERIMENTAL
Intervention: Monatepil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 86
Study: 3262598

Group type: EXPERIMENTAL
Intervention: Ascorbate (3 grams daily for 14 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30126675

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 28961848

Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m2 every 3 weeks)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 675

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 675
Study: 26308048

Group type: EXPERIMENTAL
Intervention: Evidence-based dietary intervention based on the Mediterranean and Portfolio diets
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 42
Study: 23081873

Group type: EXPERIMENTAL
Intervention: Single-dose systemic methotrexate (MTX)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 73
Study: 21946399

Group type: EXPERIMENTAL
Intervention: hotpack + ultrasound + exercise
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: hotpack + laser + exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: hotpack + exercise
Number of subjects: 52
Study: 19049696

Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir DF (200/300 mg q.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Emtricitabine/Tenofovir DF and Tacrolimus
Number of subjects: 0
Study: 16971718

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy and postoperative chemotherapy
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy and postoperative chemotherapy
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy adherence
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy adherence
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 1011
Study: 12684151

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 micro g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15803441

Group type: EXPERIMENTAL
Intervention: Drop-the-loser rule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equal allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other adaptive urn designs
Number of subjects: 0
Study: 10025903

Group type: EXPERIMENTAL
Intervention: VIM3ARAC regimen (teniposide, ifosfamide, mitoxantrone, mitoguazone, high-dose methotrexate, high-dose cytarabine, prednisolone)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: VIM3ARAC regimen followed by stem-cell transplantation (SCT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: SCT (36 patients underwent SCT: 3 allogeneic, 33 autologous)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall survival after treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Relapse off therapy and performance status <2 at relapse
Number of subjects: 71
Study: 8749083

Group type: EXPERIMENTAL
Intervention: Lateral acceleration steps of 0.05 g, 0.1 g, 0.24 g of 600 ms duration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pursuing moving targets at similar distances and accelerations
Number of subjects: 6
Study: 2375136

Group type: EXPERIMENTAL
Intervention: 400 mg QS liquid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: two 200 mg QS tablets
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 550 mg QP liquid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: two 275 mg QP tablets
Number of subjects: 13
Study: 6448618

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31976639

Group type: EXPERIMENTAL
Intervention: modified group‐based high intensity aerobic interval training (m‐Ullevaal)
Number of subjects: 120

Group type: COMPARATOR
Intervention: moderate‐intensity continuous training (MICT)
Number of subjects: 120
Study: 30805908

Group type: EXPERIMENTAL
Intervention: Electrodermal biofeedback device (RegMatEx)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo biofeedback
Number of subjects: 1015
Study: 28314093

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic (PGx)‐guided treatment
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 237
Study: 25675201

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23401486

Group type: EXPERIMENTAL
Intervention: Sustained Physical Activity (SUS-PA)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Unsustained Physical Activity (UNSUS-PA)
Number of subjects: 170

Group type: COMPARATOR
Intervention: LO-PA (Low Physical Activity)
Number of subjects: 170
Study: 21323031

Group type: EXPERIMENTAL
Intervention: Kenneth Reed technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gow-Gates technique
Number of subjects: 60
Study: 18937820

Group type: EXPERIMENTAL
Intervention: Mild laser treatment
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 17471598

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 15149424

Group type: EXPERIMENTAL
Intervention: Long QT syndrome (LQT1, LQT2, LQT3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LQT2 and LQT3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 11232948

Group type: EXPERIMENTAL
Intervention: Megestrol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Megestrol plus Tamoxifen
Number of subjects: 66
Study: 9528198

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.15%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine 0.15%
Number of subjects: 20
Study: 7874855

Group type: EXPERIMENTAL
Intervention: 600 ms neck suction (-40 mmHg) to the carotid sinus region
Number of subjects: 11

Group type: COMPARATOR
Intervention: No stimulus (anticipation control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Loud whistle (alerting control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neck suction
Number of subjects: 11
Study: 29661570

Group type: EXPERIMENTAL
Intervention: Hip exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quadriceps exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 26354729

Group type: EXPERIMENTAL
Intervention: Circuit training (2 sessions per week for 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 26291307

Group type: EXPERIMENTAL
Intervention: Robotic milling
Number of subjects: 54

Group type: COMPARATOR
Intervention: Manual rasping
Number of subjects: 54
Study: 23793205

Group type: EXPERIMENTAL
Intervention: Essential oil of Cymbopogon citratus at 1.25 μL/mL concentration, applied three times a week as shampoo and twice a day as cream for 40 days.
Number of subjects: 67

Group type: COMPARATOR
Intervention: 2% ketoconazole formulations, applied as control for 40 days.
Number of subjects: 67
Study: 21435251

Group type: EXPERIMENTAL
Intervention: STA OP!‐protocol (training and implementation)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control condition (general training focusing on challenging behaviour and pain)
Number of subjects: 168
Study: 19017467

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 16902744

Group type: EXPERIMENTAL
Intervention: Heavyweight PP mesh (Prolene 10 x 15 cm, 1.5 g, group I, n = 232)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Mixed PP- and Polyglactin mesh (Vypro II, 10 x 15 cm, 0.53 g, group II, n = 217)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Light-weight titanized PP mesh (Ti-Mesh, 10 x 15 cm, 0.24 g, group III, n = 223)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Heavy-weight PP meshes (group I+II)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 672
Study: 14602749

Group type: EXPERIMENTAL
Intervention: Recombinant human GH for 9 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10934182

Group type: EXPERIMENTAL
Intervention: Screening for four disorders in the intervention group (576 subjects) during the first year.
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Control group (545 subjects) not screened in the first year.
Number of subjects: 1121
Study: 8677083

Group type: EXPERIMENTAL
Intervention: Membrane stripping
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (weekly pelvic examinations only)
Number of subjects: 120
Study: 1569469

Group type: EXPERIMENTAL
Intervention: Goal-directed pointing movements executed at normal speed to a small visual target with a target shifted 10 degrees in a random direction during the movement.
Number of subjects: 0